GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal

PartnershipHMPL-A830Positive

AI Analysis

Summary

GSK has licensed HUTCHMED's HMPL-A830, an antibody-targeted therapy conjugate for solid tumours, in a deal worth up to $1.3 billion. HMPL-A830 selectively delivers therapeutic drugs to cancer cells while sparing healthy tissue.

Importance:7/10

Sentiment:

0.70

licensing dealpartnershiponcologyantibody-drug conjugatesolid tumours

Related Companies

$GSK $HMDCF

Read the original article

Published by Pharmaceutical Technology on September 3, 2026 10:57 AM

Read Original